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Use of horseradish peroxidase for gene-directed enzyme prodrug
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Gene therapy is a potential method of treating cancer with a greater degree of targeting than conventional therapies. In addition,
therapy can be directed towards cells within the tumour population that are traditionally resistant to current treatment schedules.
Horseradish peroxidase (HRP) can oxidise paracetamol to N-acetyl-p-benzoquinoneimine via a one-electron pathway. Incubation of
human cells expressing HRP with 0.5–10 mM paracetamol reduced clonogenic survival, but had little effect on control cells. A small
increase in apoptosis was seen and a decrease in the number of cells undergoing mitosis, consistent with reports in hepatocytes using
higher paracetamol concentrations. The cytotoxicity was also seen under conditions of severe hypoxia (catalyst induced anoxia),
indicating that the HRP/paracetamol combination may be suitable for hypoxia-targeted gene therapy.
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A number of gene therapy strategies have been proposed for the
treatment of cancer. One system is gene-directed enzyme prodrug
therapy, or GDEPT. Gene-directed enzyme prodrug therapy is a
two-step process which involves the delivery of a gene encoding an
enzyme, followed by administration of a nontoxic prodrug, which
is converted to a cytotoxin by the enzyme. Several GDEPT
combinations have been proposed (Springer and Niculescu-Duvaz,
1996), the most studied being the Herpes Simplex virus thymidine
kinase/gancyclovir system (van Dillen et al, 2002). This combina-
tion has entered clinical trials, and shown safety and some efficacy
(Sandmair et al, 2000; Miles et al, 2001).
Gene-directed enzyme prodrug therapy can be used to
selectively target tumour tissue using tissue or environmentally
controlled gene expression. In particular, the hypoxic regions of
tumours are an attractive target, since severe hypoxia is a tumour-
specific condition, and an adverse prognostic factor (Brown and
Giaccia, 1998).
The horseradish peroxidase enzyme (HRP) has previously been
used to activate indole-3-acetic acid (IAA) and related indoles, as a
GDEPT strategy (Greco et al, 2000). Horseradish peroxidase
catalyses the one-electron oxidation of IAA to the skatole radical,
which can undergo a further series of nonenzymatic reactions
prior to formation of the cytotoxin (Folkes and Wardman, 2001).
The HRP/IAA combination has shown activity under hypoxia
(Greco et al, 2001), making it suitable for targeting hypoxic regions
of tumours. In addition, when transcription of HRP gene
expression was placed under the control of hypoxia responsive
elements (HREs), the combination showed selective cell kill after
hypoxic incubation (Greco et al, 2002a).
Paracetamol (acetaminophen) is a widely used analgesic. Its
pharmacokinetic and toxicity profiles are widely known and
extensively researched. Therefore, it would not require clinical
evaluation as a prodrug alone. In cases of overdose, however, the
normal elimination pathways become saturated, often due to
glutathione (GSH) depletion, and liver damage develops due to the
production of N-acetyl-p-benzoquinoneimine (NAPQI) by cyto-
chrome P450 (CYP) enzymes (Dahlin et al, 1984). Alterations in
cell cycle progression have also been observed. Horseradish
peroxidase has been shown to catalyse the one-electron oxidation
of paracetamol to its semiquinone, which can then form
polymerisation products, or disproportionate to NAPQI (Potter
and Hinson, 1987).
The aim of the current study was to determine whether an HRP/
paracetamol combination was capable of producing a cytotoxic
species in a GDEPT setting and, in particular, whether it would be
suitable for targeting radioresistant hypoxic cells.
MATERIALS AND METHODS
Cell culture
Human nasopharyngeal squamous cell carcinoma cells, FaDu, were
obtained from the American Type Culture Collection (Manassa,
VA, USA). These cells carry a nonsense mutation within the p53
gene (Reiss et al, 1992). Cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM, Life Technologies, Paisley, UK),
supplemented with 10% fetal calf serum (Sigma, Poole, UK) and
2 mM L-glutamine (Life Technologies). Cells were kept in a
humidified incubator at 371C and 5% CO2/air. Cells were routinely
sub-cultured in 75 cm2 cantilevered flasks.
Cells were transfected with either the HRP gene (pssHRP-puro,
kindly provided by Dr O Greco, Gray Cancer Institute), or
the marker green fluorescent protein (GFP, pEGFP-puro) using a
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nonviral method, as previously described (Greco et al, 2000).
Stably transfected clones were selected in media containing
1 mg ml1 puromycin (Sigma), which resulted in the death
of parental cells within 72 h, and colonies isolated. Gene
expression was confirmed by fluorescent-activated cell sorting
(FACS) for GFP or HRP enzyme activity, using a modified
TMB assay (Greco et al, 2000). Horseradish peroxidase activity
was seen in HRP and not GFP transfectants. Single clones
were isolated, named HRP8 and GFP1, and cell lines derived
from these initial clones were used throughout the experiments.
Horseradish peroxidase activity expressed as units per mg
protein were 0.0870.003 and 0.00270.01 for HRP8 and GFP1
cells, respectively. Cells were confirmed as mycoplasma negative
using a PCR method (ATCC Mycoplasma Detection Kit
Version 2.0).
Clonogenic assay
Exponentially growing cells were collected from monolayer culture
by trypsinisation and plated at low density. Cells were plated as
either GFP1 or HRP8, or a mixture of 50% GFP1 and 50% HRP8
cells. Cells were allowed to adhere for 4 –6 h. Prodrugs were
dissolved in Hanks’ balanced salt solution (HBSS, Life Technol-
ogies) and cells were exposed in the 371C incubator for 4 or 24 h.
Following drug exposure, cells were washed in phosphate-
buffered saline (PBS) and grown for approximately 10 days in
complete media supplemented with feeder cells (V79 cells exposed
to 250 Gy 60Co). Colonies were fixed in 0.5% methylene blue w v1
in isomethylated spirit (IMS). Colonies estimated to be greater
than 50 cells were counted, and the survival was expressed relative
to vehicle-treated controls.
For experiments conducted under anoxic conditions, cells were
plated on oxygen impermeable permanox dishes (Nunc), allowed
to attach and then moved to an anoxic chamber (Don Whitley
Scientific), and media were replaced. After an hour, cells were
exposed to prodrug in the chamber. After incubation, medium was
removed, cells were washed, and incubated with feeder cells as
before. Media and prodrug solutions were kept under anoxia for at
least 14 h before addition to cells.
Glutathione measurements
The GSH level in cells was measured using a commercially
available kit (Cayman Chemical, Ann Arbor, MI, USA), following
the manufacturer’s instructions. Glutathione reacts with Ehlman’s
reagent to form a yellow coloured 5-thio-2-nitrobenzoic acid
(TNB) and a mixed disulphide. The disulphide is reduced by
glutathione reductase to recycle the TNB and form further
GSH. The rate of TNB production is proportional to the
recycling reaction, which is proportional to the concentration of
GSH in the sample.
Cells (5 105) were collected by scraping and centrifugation.
The cell pellet was resuspended and sonicated in phosphate buffer
containing 1 mM EDTA. This was centrifuged and the supernatant
deproteinated with an equal volume of metaphosphoric acid
(MPA, Aldrich, Poole, UK), centrifugation, and treatment with
50 ml of 4 M triethanolamine per millilitre of sample.
Samples were then added to a 96-well plate (TPS), and assay
cocktail was added and absorbance at 415 nm was measured every
5 min for 20 min on a Labtech plate reader. GSH levels were
calculated by producing a standard curve of known GSH
concentrations.
Cell cycle analysis
Cells were exposed to paracetamol as for clonogenic assays.
Following 24 h exposure, cells were washed, and full medium was
added for a further 24 h. Cells were then harvested, washed in PBS,
fixed in ice-cold 70% ethanol for an hour on ice, rinsed,
centrifuged, and the pellet resuspended in a solution containing
20 mg ml1 propidium iodide, 20 mg ml1 RNAse A (Sigma) in PBS.
Cells were incubated at 371C for 30 min, and then analysed by
FACS (Becton Dickson, Cowley, Oxford, UK), gated to exclude
cellular debris.
Effect of furafylline on HRP activity
Purified HRP enzyme (0.4 ng, Sigma) was incubated in the
presence of varying concentrations of the CYP1A2 inhibitor,
furafylline (Sigma), in 80 mM phosphate buffer (pH 5.4). Then,
320 mM 3,30,5,50-tetramethylbenzidine (TMB) and 3 mM hydrogen
peroxide were added to give a total volume of 2 ml. Absorbance
was read every minute at 652 nm for 10 min on a Hewlett Packard
model 8452A diode array spectrophotometer. Over this period,
absorbance increased linearly.
Statistical analysis
JMP statistical analysis programme was used to carry out ANOVA
and t-test analyses.
RESULTS
Incubation with paracetamol for 4 h resulted in a decreased
clonogenic ability of FaDu cells stably expressing the HRP enzyme
(HRP8). Concentrations of 1 mM prodrug resulted in greater than
50% cell kill (Figure 1A). Concentrations greater than 1 mM did not
appear to further increase the cell kill. There was no loss of
viability in GFP controls up to 8 mM paracetamol.
After 24 h exposure to paracetamol, clonogenic survival of HRP8
cells decreased sharply with increasing concentrations of prodrug,
with over a log of cell kill at 10 mM paracetamol (Figure 1C).
However, the extended incubation resulted in a loss of GFP1
clonogenicity, although to a lesser extent than HRP8.
To determine whether the HRP/paracetamol combination would
be suitable for hypoxia targeting, the clonogenic studies were
repeated under anoxic conditions. After both 4 and 24 h exposure
to paracetamol (Figure 1B and D), HRP8 cells showed a similar
decrease in clonogenic survival as under oxic conditions. The IC50
values (concentration required to decrease the surviving fraction
by 50%) did not differ between the two oxygen status experiments
at either exposure time.
Exposure of a mixture of HRP8 and GFP1 cells to paracetamol
for 24 h under oxic or anoxic conditions (Figure 1) resulted in cell
kill that almost overlapped with that seen in experiments with
HRP8 only cells, indicating a large bystander effect.
There was no significant difference in either the oxidised or
reduced form of GSH between HRP8 or GFP1 cells as determined
by the recycling assay (Figure 2). There was a slight but not
significant difference between GSx levels in parental FaDu cells and
HRP8 and GFP1 clones.
Propidium iodide staining of cells showed a significant increase
in the sub-G1 cell population of HRP8 cells following incubation
with paracetamol compared with untreated controls (Figure 3).
There was also a small decrease in the number of G2/S cells
indicating a decrease in proliferation. In contrast, there was
no statistically significant change in the cycle distribution of
GFP1 cells.
In experiments using purified HRP enzyme, incubation with up
to 25 mM furafylline (a potent cytochrome P450 1A2 inhibitor) led
to a maximum decrease of 20% in the enzyme activity (Figure 4).
Concentrations of furafylline required to decrease the enzymatic
activity of purified HRP enzyme by half were not attainable as the
solubility limit of the drug was reached at 250mM.
Gene therapy using paracetamol
J Tupper et al
1859
British Journal of Cancer (2004) 90(9), 1858 – 1862& 2004 Cancer Research UK
E
x
p
e
ri
m
e
n
ta
l
T
h
e
ra
p
e
u
ti
c
s
DISCUSSION
The results presented here show the ability of the HRP enzyme to
catalyse the conversion of paracetamol to a cytotoxin intracellu-
larly. This enzyme/prodrug combination was effective under both
oxic and anoxic conditions, with no loss of activity in the absence
of oxygen. In addition, mixtures of HRP-expressing and nonex-
pressing cells showed almost equivalent levels of cell kill to HRP
only experiments, indicating a large bystander effect.
The potential of delivering the HRP gene to activate IAA has
been shown previously (Greco et al, 2000). In the present study,
paracetamol was used as an alternative prodrug to indoles.
Sufficient cytotoxin was produced to decrease the clonogenic
ability of HRP transfectants both under oxic and anoxic
conditions. This effect appears to be independent of p53, since
FaDu cells carry a nonsense mutation at codon 248 (Reiss et al,
1992).
The toxicity of the HRP/paracetamol combination is likely to be
a result of NAPQI formation. However, the exact mechanism is
currently unclear. The data showed a slight increase in apoptosis,
as indicated by an increased sub-G1 peak of treated cells after
propidium iodide staining, and also a decrease in the number of
cells undergoing mitosis (increased G2/M population). However,
this may be supplemented by necrosis, since this is the primary
finding in vivo following overdose (Timbrell, 1996), and the
decrease in clonogenicity seen following paracetamol exposure
could not be fully explained by apoptosis. Further experiments are
required to determine the exact route of cell death and mechanism
of action.
Paracetamol/NAPQI is able to deplete cellular GSH levels
(Adamson and Harman, 1993; Pumford et al, 1997), bind to
proteins and DNA (Pumford et al, 1997), increase intracellular
calcium concentrations (Tsokos-Kuhn, 1989), cause lipid
peroxidation, increase reactive oxygen species (Manov et al,
2002), and has been shown to affect cell cycle progression and
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Figure 1 Clonogenic survival of cells following exposure to paracetamol. (A) 4 h air, (B) 4 h in anoxia (catalyst induced), (C) 24 h air, (D) 24 h anoxia.
Data are mean7s.e.m. three experiments, triplicate samples. K GFP1 controls, & HRP8 cells,  mixture of 50% HRP8 and 50% GFP1 cells (mosaic).
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Figure 2 Glutathione concentrations in FaDu cells measured using the
recycling assay. ’ FaDu parental cells, & GFP1 clones, HRP8 clones.
Data are mean7s.d. two experiments, duplicate samples.
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DNA synthesis (Djordjevic et al, 1986; Richard et al, 1991). There
is some controversy over which mechanism is most important, and
its, likely that all play a role, with different mechanisms
predominating under differing conditions. These effects, described
in the literature, were seen in cells where NAPQI production would
be due to a direct two-electron oxidation by CYP enzymes. In
the case of activation by HRP via one-electron oxygenation,
it is possible that there could be constant recycling of the
semiquinone back to paracetamol with little formation of NAPQI,
provided there is sufficient GSH or NADPH (preferentially GSH
(Potter and Hinson, 1987)). This in itself would lead to oxidative
stress, and may increase the susceptibility of cells to damage
by ionising radiation. Radiotherapy is a standard treatment for
many solid tumours, and its combination with GDEPT strategies is
promising (Buchsbaum et al, 1996). In fact, the HRP/IAA
combination sensitised cells to radiation in air and hypoxia
(Greco et al, 2002b). Hence, future work is aimed at deter-
mining whether the HRP/paracetamol combination would act as
radiosensitizer.
There was no detectable difference in GSH levels between
GFP1 and HRP8 cells, indicating that the increased susceptibility
of HRP8 transfectants to paracetamol is unlikely to be due to
an exacerbation of an imbalanced oxidative state. It has
previously been reported that the addition of HRP to cells can
decrease GSH levels (Harman et al, 1986). From our results it
appears that the constant production of the enzyme intracellularly
has no greater effect on GSH concentrations than the production
and persistence of GFP. Overall, however, transfected cells tended
to have lower GSH levels than untransfected FaDu cells. This
could be due to either the presence of the transgene, or may
be a consequence of the presence of puromycin antibiotic in the
growth media.
The concentrations of paracetamol used to achieve cell kill are
similar to those used by Thatcher et al (2000) for prodrug
activation using CYP1A2. This group showed decreased cell
viability following exposure of fibroblasts overexpressing CYP1A2
to paracetamol. The levels used in both studies are greater than
those achievable after current therapeutic doses of paracetamol.
However, it may be possible to increase paracetamol doses in
patients by combining treatment with furafylline, a potent CYP1A2
inhibitor (Sesardic et al, 1990). Plasma steady-state levels of
furafylline can reach 5.8 mM in humans (Tarrus et al, 1987), and the
IC50 for purified CYP1A2 is 0.07 mM (Sesardic et al, 1990),
indicating that the use of furafylline to inhibit paracetamol
activation in the liver is feasible. Importantly for our study,
furafylline had little effect on HRP enzyme activity up to 25 mM.
Orally administered methionine or N-acetyl cysteine could also be
administered to increase liver GSH levels (McLean and Day, 1975;
Aebi and Lauterburg, 1992). This would decrease the susceptibility
of the liver to damage by NAPQI by allowing increased amounts of
mercapturic acid to be formed, as well as N-acetylcysteine
conjugates. Although somewhat effective at minimising damage
following paracetamol overdose, the effect of GSH precursors
administered prior to paracetamol in combination with furafylline
needs to be assessed.
In conclusion, this data demonstrates for the first time the
potential for HRP/paracetamol as a GDEPT strategy, under tumour
conditions. Further work needs to be carried out to determine the
mechanism of action, the in vivo potential and possible radio-
sensitising effects before speculating on clinical trial outcome.
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